Who Are The Top Investors In Sangamo Therapeutics Inc (SGMO)? Fri, 24 Nov 2017 19:35:11 +0000 In this article, I will take a quick look at Sangamo Therapeutics Inc’s (NASDAQ:SGMO) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure has beenRead More...
Sangamo Therapeutics, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Fri, 24 Nov 2017 18:01:00 +0000 RICHMOND, Calif., Nov. 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) announced today that the Compensation Committee of the Company's Board of Directors approved the grant effective on November 22, 2017 of inducement stock options to purchase a total of 164,000 shares of common stock to four new employees. The stock options have an exercise price per share equal to $15.00, the fair market value on the grant date, November 22, 2017. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee's continued service relationship with the Company on each such date.
ETFs with exposure to Sangamo Therapeutics, Inc. : November 21, 2017 Tue, 21 Nov 2017 17:12:12 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sangamo Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SGMO-US. Comparing the performance and risk of Sangamo Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : November 17, 2017 Fri, 17 Nov 2017 18:55:26 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Sangamo Therapeutics, Inc. a score of 14. Our analysis is based on comparing Sangamo Therapeutics, Inc. with the following peers – Alnylam Pharmaceuticals, Inc, Gilead Sciences, Inc., Amgen Inc., Merck & Co., Inc., BioMarin Pharmaceutical Inc., Johnson & Johnson, DowDuPont Inc., Shire PLC Sponsored ADR, Biogen Inc. ... Read more
(Read more...)
Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : November 16, 2017 Thu, 16 Nov 2017 12:06:03 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sangamo Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II Wed, 15 Nov 2017 06:10:00 +0000 RICHMOND, Calif., Nov. 15, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Sangamo aims to treat MPS II by using genome editing to insert a corrective gene into a precise location in the DNA of liver cells with the goal of enabling a patient's liver to produce a lifelong and stable supply of an enzyme he or she currently lacks. Without that enzyme, called iduronate-2-sulfatase (IDS), people with MPS II suffer debilitating buildup of toxic carbohydrates in cells throughout their body.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.16 (median winner: 1.53)
Above 40wkMA: 59% (median winner: 35%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.